Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.5%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares shot up 7.5% on Thursday . The stock traded as high as $28.14 and last traded at $27.96. 26,710 shares traded hands during trading, a decline of 86% from the average session volume of 185,149 shares. The stock had previously closed at $26.00.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating for the company. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $44.71.

Dianthus Therapeutics Trading Down 0.4 %

The company’s 50-day moving average is $27.98 and its two-hundred day moving average is $26.14. The firm has a market cap of $821.77 million, a P/E ratio of -4.80 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the period. Bank of New York Mellon Corp lifted its stake in Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares during the last quarter. Octagon Capital Advisors LP increased its position in Dianthus Therapeutics by 15.4% in the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after buying an additional 74,000 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $1,404,000. Finally, SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $112,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.